Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA)

Abstract Background: Circulating tumour DNA (ctDNA) is considered to have a high potential for future management of malignancies. This pilot external quality assessment (EQA) scheme aimed to address issues of analytical quality in this new area of laboratory diagnostics. Methods: The EQA scheme consisted of three 2-mL EDTA-plasma samples spiked with fragmented genomic DNA with a mutant allele frequency ranging from 0% to 10% dedicated to the analysis of nine known sequence variations in KRAS codon 12/13 and of BRAF V600E. Laboratories reported: (1) time elapsed for processing, (2) storage temperatures, (3) methods for extraction and quantification, (4) genotyping methodologies and (5) results. Results: Specimens were sent to 42 laboratories from 10 European countries; 72.3% reported to isolate cell-free DNA (cfDNA) manually, 62.5% used the entire plasma volume for cfDNA isolation and 38.5% used >10% of cfDNA extracted for downstream genotyping. Of the methods used for quantification, PicoGreen demonstrated the lowest coefficient of variation (33.7%). For genotyping, 11 different methods were reported with the highest error rate observed for Sanger sequencing and the lowest for highly sensitive approaches like digital PCR. In total, 197 genotypes were determined with an overall error rate of 6.09%. Conclusions: This pilot EQA scheme illustrates the current variability in multiple phases of cfDNA processing and analysis of ctDNA resulting in an overall error rate of 6.09%. The areas with the greatest variance and clinical impact included specimen volume, cfDNA quantification method, and preference of genotyping platform. Regarding quality assurance, there is an urgent need for harmonisation of procedures and workflows.

[1]  H A Erlich,et al.  Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. , 1986, Nature.

[2]  Henry A. Erlich,et al.  Analysis of enzymatically amplified β-globin and HLA-DQα DNA with allele-specific oligonucleotide probes , 1986, Nature.

[3]  H A Erlich,et al.  Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Spitzer,et al.  Single nucleotide primer extension to detect genetic diseases: experimental application to hemophilia B (factor IX) and cystic fibrosis genes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S H Neoh,et al.  Quantitation of targets for PCR by use of limiting dilution. , 1992, BioTechniques.

[6]  P. Vos,et al.  AFLP: a new technique for DNA fingerprinting. , 1995, Nucleic acids research.

[7]  M. Neumaier,et al.  Experiences with External Quality Assessment (EQA) in Molecular Diagnostics in Clinical Laboratories in Germany , 2000, Clinical chemistry and laboratory medicine.

[8]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[9]  W. Grody,et al.  Quality control in molecular genetic testing , 2001, Nature Reviews Genetics.

[10]  S. Little,et al.  Amplification‐Refractory Mutation System (ARMS) Analysis of Point Mutations , 1995, Current protocols in human genetics.

[11]  Frank Diehl,et al.  Detection and quantification of mutations in the plasma of patients with colorectal tumors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Frank Diehl,et al.  BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions , 2006, Nature Methods.

[13]  M. Fleischhacker,et al.  Circulating nucleic acids (CNAs) and cancer--a survey. , 2007, Biochimica et biophysica acta.

[14]  K. Kinzler,et al.  Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. , 2007, Cancer research.

[15]  P. Pernet,et al.  Specific real-time PCR vs. fluorescent dyes for serum free DNA quantification , 2007, Clinical chemistry and laboratory medicine.

[16]  G. Makrigiorgos,et al.  COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. , 2009, Biochemical Society transactions.

[17]  V. Sintchenko,et al.  Multiplex PCR and Reverse Line Blot Hybridization Assay (mPCR/RLB) , 2011, Journal of visualized experiments : JoVE.

[18]  Cas Weykamp,et al.  Proficiency testing/external quality assessment: current challenges and future directions. , 2011, Clinical chemistry.

[19]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[20]  Kikuya Kato,et al.  Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas , 2011, Clinical Cancer Research.

[21]  Sarah Berwouts,et al.  Quality assurance practices in Europe: a survey of molecular genetic testing laboratories , 2012, European Journal of Human Genetics.

[22]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[23]  Jorge S. Reis-Filho,et al.  Going with the Flow: From Circulating Tumor Cells to DNA , 2013, Science Translational Medicine.

[24]  M. Zavoral,et al.  Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. , 2013, Analytical biochemistry.

[25]  Daniel F. Hayes,et al.  Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer , 2013 .

[26]  S. Gelmini,et al.  SPIDIA-DNA: an External Quality Assessment for the pre-analytical phase of blood samples used for DNA-based analyses. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[27]  R. Murthy,et al.  Use of research biopsies in clinical trials: are risks and benefits adequately discussed? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Mouliere,et al.  Circulating cell free DNA: Preanalytical considerations. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[29]  Alison S. Devonshire,et al.  Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification , 2014, Analytical and Bioanalytical Chemistry.

[30]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[32]  フランク ディール,et al.  Circulating mutant dna to assess tumor dynamics , 2015 .

[33]  Matthew Wongchenko,et al.  Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.

[34]  W. Tam,et al.  Novel therapeutic targets on the horizon for lung cancer. , 2016, The Lancet. Oncology.

[35]  Matthew W. Snyder,et al.  Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin , 2016, Cell.

[36]  H. Dosaka-akita,et al.  Role of targeted therapy in metastatic colorectal cancer , 2016, World journal of gastrointestinal oncology.

[37]  V. Haselmann,et al.  Thirteen Years of an International External Quality Assessment Scheme for Genotyping: Results and Recommendations. , 2016, Clinical chemistry.

[38]  N. Dhomen,et al.  Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. , 2016, Cancer discovery.

[39]  A. Torkamani,et al.  Liquid Biopsies for Cancer: Coming to a Patient near You , 2017, Journal of clinical medicine.